NeuroPace (NPCE) Common Equity (2020 - 2026)

NeuroPace has reported Common Equity for 7 years, with the latest figure at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 40.44% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (down 40.44% YoY), and the FY2025 full-year result was $19.0 million, up 137.5% from the prior year.
• Common Equity for Q1 2026 stood at $14.5 million, down from $19.0 million in the prior quarter.
• The five-year high for Common Equity was $62.8 million in Q1 2022, with the low at $8.0 million in Q4 2024.
• Average Common Equity over 5 years is $24.6 million, with a median of $19.4 million recorded in 2025.
• Year-over-year, Common Equity surged 140.16% in 2022 and slumped 62.31% in 2023.
• Tracing NPCE's Common Equity over 5 years: stood at $34.8 million in 2022, then tumbled by 40.61% to $20.7 million in 2023, then plunged by 61.2% to $8.0 million in 2024, then jumped by 137.5% to $19.0 million in 2025, then retreated by 24.05% to $14.5 million in 2026.
• The last three Common Equity figures came in at $14.5 million (Q1 2026), $19.0 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.

Peer Comparison